[September 23-27, 2012]
Rio de Janeiro, Brazil

DNDi hosted two session in the XVIII International Congress for Tropical Medicine and Malaria.

See a Summary of DNDi‘s activities!

Closed session: 24 September, 19h-19h30

Cocktail Reception: Product Development Partnerships (PDPs) for Neglected Diseases
Co-hosted by the Medicines for Malaria Venture (MMV) and DNDi

See invitation
See programme

Session I: 25 September, 09h00-11h00
Progressing NCEs through clinical development for the treatment of neglected tropical diseases

Chair: Els Torreele, Director of the Public Health Program’s Access to Essential Medicines Initiative, Open Society Foundation

Abstract: This session aimed to give an overview of the realities of developing new drugs for the treatment of neglected tropical diseases, and to present DNDi’s model of progressing NCEs through the development pipeline, with a focus on the main element of success, strong partnerships. [complete abstract PDF]


 High throughput screening – Lucio Freitas-Junior, IPK

 E1224 for Chagas disease: news on a drug candidate from a promising class – Isabela Ribeiro, Head of DNDi’s Clinical Programme in Chagas disease & Frederick Duncanson, Eisai

Nitroimidazoles as a potential new series for visceral leishmaniasis – Fexinidazole and VL-2098  Shyam Sundar, Professor of Medicine, Institute of Medical Sciences Banaras Hindu University (BHU), Varanasi, India


Session II: 25 September, 16h45-18h45
Developing safe and efficacious drugs to treat Chagas disease 

Chair: Isabela Ribeiro, Head of Chagas Clinical Program, DNDi

Abstract: The session explored the current state of the Chagas disease portfolio and gave an overview of what is needed to provide patients with a safe, efficacious, easy-to-use and affordable treatment, with a focus on early drug discovery and assessment of treatment efficacy. [complete abstract PDF]


 Early medicinal chemistry to identify new candidate drugs – Martine Keenan, Head of Drug Discovery, Epichem

 Potential drug candidate series: nitroimidazoles and fenarimols – Eric Chatelain, Head of Chagas Discovery & Preclinical Program, DNDi

 Efficacy, safety and population pharmacokinetics of benznidazole in children: presentation of results – Dr. Jaime Altcheh, Ricardo Gutiérrez Children’s Hospital

 Optimization of sampling procedure for PCR technique to assess parasitological response for patients with Chronic Chagas Disease treated with benznidazole in Aiquile, Bolivia’ – preliminary results – Laurence Flevaud, MSF – Spain


Workshop, 26 September, 14:00-15:30
Protozoan: African Trypanosomiasis 

 Fexinidazole for HAT – Olaf Valverde, Antoine Tarral, Séverine Blesson, Virginie Gualano, Mathieu Felices, Lionel Hovsepian, Eric Evene, Pascal Voiriot, Nathalie Strub-Wourgaft



More information:
Congress website